News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evotec AG (EVTG.F) and Roche (RHHBY) to Develop EVT 101 for Treatment-Resistant Depression; Deal Valued at More Than $300 Million



3/9/2009 9:38:38 AM

HAMBURG, Germany and BASEL, Switzerland, March 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) and Roche (SWX: RO, ROG; OTCQX: RHHBY) announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds USD 300 million.

Read at GlobeNewswire


comments powered by Disqus
Evotec AG
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES